http://www.biofusion.co.uk/News/ Keep updated with Biofusion's latest news. 10 Wed, 16 Apr 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, is pleased to announce its Interim Results for the six months ended 31 January 2008.... http://www.biofusion.co.uk/News/BFN+Interims+2008.htm?p=1 Mon, 14 Apr 2008 00:00:00 GMT Simcyp, the leader in predictive pharmacokinetics, today announces the release of the 2008 version of the Simcyp Paediatric Simulator, a modelling and simulation platform which provides valuable information relevant to first-time dosing decisions and the design of clinical studies in... http://www.biofusion.co.uk/News/Simcyp+paediatric+sim+2008.htm?p=1 Wed, 2 Apr 2008 00:00:00 GMT Simcyp Limited, the leader in predictive pharmacokinetics, has released Version 8.0 of the ‘Simcyp Population-based ADME Simulator’, an advanced platform for the modelling and simulation of drug absorption, distribution, metabolism and elimination (ADME) in virtual populations. The new features incorporated... http://www.biofusion.co.uk/News/Simcyp+launches+V8+Apr+08.htm?p=1 Fri, 28 Mar 2008 00:00:00 GMT LGC Standards, Europe’s leading supplier of reference standards, in combination with Abcellute Ltd, a Cardiff(UK)-based biotech company, have signed a commercial agreement to bring a revolutionary new approach to the preservation of hepatocyte cells for use in preclinical drug discovery... http://www.biofusion.co.uk/News/Abcellute+LGC+agreement.htm?p=1 Wed, 26 Mar 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into world-class business, today announces that it has made an additional  investment of £265,000 in Asterion Limited (“Asterion”), a portfolio company from Biofusion’s University of Sheffield... http://www.biofusion.co.uk/News/Asterion+£265k+investment.htm?p=1 Mon, 17 Mar 2008 00:00:00 GMT Simcyp Limited today announces the appointment of Professor Carl Peck to the Simcyp Scientific Advisory Board. Professor Peck is the founding Director of the Center for Drug Development Science at UCSF, a former Director of the US FDA Center for... http://www.biofusion.co.uk/News/Simcyp+stengthens+SAB+Mar+08.htm?p=1 Tue, 4 Mar 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, is today pleased to note that Phoqus Pharmaceuticals plc (“Phoqus”), the speciality pharmaceutical company  that is working in collaboration with Biofusion’s subsidiary company Diurnal... http://www.biofusion.co.uk/News/PhoqusPharmaceuticals.htm?p=1 Wed, 27 Feb 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, today announces the launch of a new portfolio company, Demasq Limited (“Demasq”), which is developing a range of innovative bone and soft tissue imaging... http://www.biofusion.co.uk/News/LaunchofDemasq.htm?p=1 Fri, 15 Feb 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, today announces that it has invested £400,000 into Phase Focus Limited (“Phase Focus”), its high resolution ‘lensless’ microscopy spin-out company from its University of... http://www.biofusion.co.uk/News/BFNPhaseFocus.htm?p=1 Fri, 11 Jan 2008 00:00:00 GMT Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, is pleased to note that Lifestyle Choices’ Plan Ahead™ test, which helps measure a woman’s ovarian reserves, has been launched in the US by... http://www.biofusion.co.uk/News/Repromedix+launch+Jan+08.htm?p=1